{"DataElement":{"publicId":"7247333","version":"1","preferredName":"Immunotherapeutic Agent Related Adverse Event Endocrine System Disorder Present Type","preferredDefinition":"Information related to the type of endocrine system disorder immunotherapeutic related adverse event that is present.","longName":"7247327v1.0:7246042v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"7247327","version":"1","preferredName":"Immunotherapeutic Agent Relationship Adverse Event Endocrine System Disorder Present","preferredDefinition":"Any substance that induces, enhances, restores or suppresses the host's immune system, or an agent that utilizes or is derived from a component of the immune system._A state of connectedness between people, objects, or events; to be associated or connected with something._Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s)._A non-neoplastic or neoplastic disorder that affects the endocrine system. Representative examples of non-neoplastic disorders include diabetes mellitus, hyperthyroidism, and adrenal gland insufficiency. Representative examples of neoplastic disorders include carcinoid tumor, neuroendocrine carcinoma, and pheochromocytoma._Being or existing in a specified place or at the specified time.","longName":"6955286v1.0:7247325v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"6955286","version":"1","preferredName":"Immunotherapeutic Agent Relationship Adverse Event","preferredDefinition":"Any substance that induces, enhances, restores or suppresses the host's immune system, or an agent that utilizes or is derived from a component of the immune system.:A state of connectedness between people, objects, or events; to be associated or connected with something.:Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","longName":"C308:C25648:C41331","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunotherapeutic Agent","conceptCode":"C308","definition":"Any substance that induces, enhances, restores or suppresses the host's immune system, or an agent that utilizes or is derived from a component of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Relationship","conceptCode":"C25648","definition":"A state of connectedness between people, objects, or events; to be associated or connected with something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adverse Event","conceptCode":"C41331","definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93EC8B94-DB7D-03ED-E053-F662850AFC99","latestVersionIndicator":"Yes","beginDate":"2019-10-02","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7247325","version":"1","preferredName":"Endocrine System Disorder Present","preferredDefinition":"A non-neoplastic or neoplastic disorder that affects the endocrine system. Representative examples of non-neoplastic disorders include diabetes mellitus, hyperthyroidism, and adrenal gland insufficiency. Representative examples of neoplastic disorders include carcinoid tumor, neuroendocrine carcinoma, and pheochromocytoma.:Being or existing in a specified place or at the specified time.","longName":"C3009:C25626","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endocrine System Disorder","conceptCode":"C3009","definition":"A non-neoplastic or neoplastic disorder that affects the endocrine system. Representative examples of non-neoplastic disorders include diabetes mellitus, hyperthyroidism, and adrenal gland insufficiency. Representative examples of neoplastic disorders include carcinoid tumor, neuroendocrine carcinoma, and pheochromocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Present","conceptCode":"C25626","definition":"Being or existing in a specified place or at the specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A35CE4F8-03DF-0F95-E053-F662850A2716","latestVersionIndicator":"Yes","beginDate":"2020-04-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-16","modifiedBy":"ONEDATA","dateModified":"2020-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A35CE4F8-03F0-0F95-E053-F662850A2716","latestVersionIndicator":"Yes","beginDate":"2020-04-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-16","modifiedBy":"MORENOC","dateModified":"2020-07-01","changeDescription":"7/1/2020: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7246042","version":"1","preferredName":"Immunotherapeutic Related Adverse Event Endocrine System Disorder Type","preferredDefinition":"The type of endocrine system disorder immunotherapeutic related adverse event.","longName":"7246042v1.0","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Adrenal","valueDescription":"Adrenal Gland Disorder","ValueMeaning":{"publicId":"7246044","version":"1","preferredName":"Adrenal Gland Disorder","longName":"7246044","preferredDefinition":"Any disease affecting the adrenal gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adrenal Gland Disorder","conceptCode":"C26690","definition":"Any disease affecting the adrenal gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3590C02-BC6F-7FFF-E053-F662850ADCB2","latestVersionIndicator":"Yes","beginDate":"2020-04-15","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-15","modifiedBy":"GDEEN","dateModified":"2024-01-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3590C02-BC88-7FFF-E053-F662850ADCB2","beginDate":"2020-04-15","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-15","modifiedBy":"ONEDATA","dateModified":"2020-04-15","deletedIndicator":"No"},{"value":"Thyroid","valueDescription":"Thyroid Gland Disorder","ValueMeaning":{"publicId":"7246045","version":"1","preferredName":"Thyroid Gland Disorder","longName":"7246045","preferredDefinition":"A non-neoplastic or neoplastic disorder that affects the thyroid gland.  Representative examples include hyperthyroidism, hypothyroidism, thyroiditis, follicular adenoma, and carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Disorder","conceptCode":"C26893","definition":"A non-neoplastic or neoplastic disorder that affects the thyroid gland.  Representative examples include hyperthyroidism, hypothyroidism, thyroiditis, follicular adenoma, and carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3590C02-BC94-7FFF-E053-F662850ADCB2","latestVersionIndicator":"Yes","beginDate":"2020-04-15","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-15","modifiedBy":"ONEDATA","dateModified":"2020-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3590C02-BCAD-7FFF-E053-F662850ADCB2","beginDate":"2020-04-15","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-15","modifiedBy":"ONEDATA","dateModified":"2020-04-15","deletedIndicator":"No"},{"value":"Diabetes","valueDescription":"Diabetes Mellitus","ValueMeaning":{"publicId":"3292684","version":"1","preferredName":"Diabetes Mellitus","longName":"3292684","preferredDefinition":"A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diabetes Mellitus","conceptCode":"C2985","definition":"A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEA65AE0-D82E-3EBD-E040-BB89AD431EBC","latestVersionIndicator":"Yes","beginDate":"2011-10-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-10-06","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3590C02-BCB7-7FFF-E053-F662850ADCB2","beginDate":"2020-04-15","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-15","modifiedBy":"ONEDATA","dateModified":"2020-04-15","deletedIndicator":"No"},{"value":"Other endocrinological condition","valueDescription":"Other Endocrine System Disorder","ValueMeaning":{"publicId":"7246046","version":"1","preferredName":"Other Endocrine System Disorder","longName":"7246046","preferredDefinition":"Different than the one(s) previously specified or mentioned.: A non-neoplastic or neoplastic disorder that affects the endocrine system. Representative examples of non-neoplastic disorders include diabetes mellitus, hyperthyroidism, and adrenal gland insufficiency. Representative examples of neoplastic disorders include carcinoid tumor, neuroendocrine carcinoma, and pheochromocytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Endocrine System Disorder","conceptCode":"C3009","definition":"A non-neoplastic or neoplastic disorder that affects the endocrine system. Representative examples of non-neoplastic disorders include diabetes mellitus, hyperthyroidism, and adrenal gland insufficiency. Representative examples of neoplastic disorders include carcinoid tumor, neuroendocrine carcinoma, and pheochromocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3590C02-BCC4-7FFF-E053-F662850ADCB2","latestVersionIndicator":"Yes","beginDate":"2020-04-15","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-15","modifiedBy":"ONEDATA","dateModified":"2020-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3590C02-BCDD-7FFF-E053-F662850ADCB2","beginDate":"2020-04-15","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-15","modifiedBy":"ONEDATA","dateModified":"2020-04-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3590C02-BC55-7FFF-E053-F662850ADCB2","latestVersionIndicator":"Yes","beginDate":"2020-04-15","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-15","modifiedBy":"MORENOC","dateModified":"2020-07-01","changeDescription":"7/1/2020: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"Alliance","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"Specify Endocrinopathic irAE","type":"Preferred Question Text","description":"Specify Endocrinopathic irAE","url":null,"context":"Alliance"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Specify irAE","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3677D94-3AA4-3CDB-E053-F662850A6457","latestVersionIndicator":"Yes","beginDate":"2020-04-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-04-16","modifiedBy":"MORENOC","dateModified":"2020-11-19","changeDescription":"7/1/2020: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}